|
Video: What is a Stock Split?
|
|
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused primarily on developing and commercializing pharmaceuticals to treat cardiometabolic diseases. Co. has two primary programs focused on treatment of nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes (T2D): DA-1241, which is a G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; as well as DA-1726, which is an oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity that is to be administered once weekly subcutaneously. According to our NRBO split history records, NeuroBo Pharmaceuticals has had 3 splits. | |
|
NeuroBo Pharmaceuticals (NRBO) has 3 splits in our NRBO split history database. The first split for NRBO took place on December 31, 2019. This was a 1 for 25 reverse split, meaning for each 25 shares of NRBO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split. NRBO's second split took place on September 13, 2022. This was a 1 for 30 reverse split, meaning for each 30 shares of NRBO owned pre-split, the shareholder now owned 1 share. For example, a 40 share position pre-split, became a 1.33333333333333 share position following the split. NRBO's third split took place on December 21, 2023. This was a 1 for 8 reverse split, meaning for each 8 shares of NRBO owned pre-split, the shareholder now owned 1 share. For example, a 1.33333333333333 share position pre-split, became a 0.166666666666667 share position following the split.
When a company such as NeuroBo Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NRBO split history from start to finish, an original position size of 1000 shares would have turned into 0.166666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NeuroBo Pharmaceuticals shares, starting with a $10,000 purchase of NRBO, presented on a split-history-adjusted basis factoring in the complete NRBO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/09/2016 |
|
End date: |
04/29/2024 |
|
Start price/share: |
$53,760.00 |
|
End price/share: |
$3.23 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.99% |
|
Average Annual Total Return: |
-71.58% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$0.60 |
|
Years: |
7.73 |
|
|
|
Date |
Ratio |
12/31/2019 | 1 for 25 | 09/13/2022 | 1 for 30 | 12/21/2023 | 1 for 8 |
|
|